PhaseBio Pharmaceuticals Income Tax

As of the most recent data (June 2022), PHAS shows a income tax of $-4.5M. That compares with $-8.2M in the prior-year period — up 45.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PHAS's income tax is now $-4.5M (was $-8.2M) — a 45.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether PhaseBio Pharmaceuticals is outperforming or lagging.

Tracking PHAS's income tax over time shows whether PhaseBio Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-4.5M That compares with $-8.2M in the prior-year period — up 45.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this income tax page, Stockcircle has PhaseBio Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect income tax (currently $-4.5M) with ownership activity and broader fundamentals.

PhaseBio Pharmaceuticals's income tax is $-4.5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.